News | 28 March 2024
WuXi Biologics breaks ground on CRDMO Center in Singapore
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
The facility will manufacture tablets, capsules, and injections for the oncology segment
Operations of Line II was stopped due to a fire incident earlier
Hepatitis B infects over 40 million people in India
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Pharma Solutions operates 10 research and development and/or production sites globally
The pilot plant is focused on scaling up beverage production and will support applications
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
To accelerate the development of next-generation radioconjugates to treat cancer
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Additional capacity broadens Grace’s fine chemical capabilities for API production
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Both organisations enter into a long- term collaboration to expand patient access in India
Subscribe To Our Newsletter & Stay Updated
